TY - JOUR
T1 - Radiolabeled protein-inhibitor peptides with rapid clinical translation towards imaging and therapy
AU - Ferro-Flores, Guillermina
AU - Ocampo-García, Blanca
AU - Gutiérrez, Myrna Luna
AU - Cuevas, Clara Santos
AU - Jiménez-Mancilla, Nallely
AU - Azorín-Vega, Erika
AU - Meléndez-Alafort, Laura
N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
PY - 2019/12/23
Y1 - 2019/12/23
N2 - Protein interactions are the basis for the biological functioning of human beings. However, many of these interactions are also responsible for diseases, including cancer. Synthetic inhibitors of protein interactions based on small molecules are widely investigated in medicinal chemistry. The development of radiolabeled protein-inhibitor peptides for molecular imaging and targeted therapy with quickstep towards clinical translation is an interesting and active research field in the radiopharmaceutical sciences. In this article, recent achievements concerning the design, translational research and theranostic applications of structurally-modified small radiopeptides such as prostate-specific membrane antigen (PSMA) inhibitors, fibroblast activation protein (FAP) inhibitors and antagonists of chemokine-4 receptor ligands (CXCR-4-L), with high affinity for cancer-associated target proteins, are reviewed and discussed.
AB - Protein interactions are the basis for the biological functioning of human beings. However, many of these interactions are also responsible for diseases, including cancer. Synthetic inhibitors of protein interactions based on small molecules are widely investigated in medicinal chemistry. The development of radiolabeled protein-inhibitor peptides for molecular imaging and targeted therapy with quickstep towards clinical translation is an interesting and active research field in the radiopharmaceutical sciences. In this article, recent achievements concerning the design, translational research and theranostic applications of structurally-modified small radiopeptides such as prostate-specific membrane antigen (PSMA) inhibitors, fibroblast activation protein (FAP) inhibitors and antagonists of chemokine-4 receptor ligands (CXCR-4-L), with high affinity for cancer-associated target proteins, are reviewed and discussed.
U2 - 10.2174/0929867327666191223121211
DO - 10.2174/0929867327666191223121211
M3 - Article
C2 - 31870259
SP - 1
EP - 12
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
ER -